Citations

Showing 10 of 108119 citations.

Living Donor Liver Transplantation: Preoperative Planning and Postoperative Complications
Hecht, Elizabeth M. , Wang, Zhen J. , Kambadakone, Avinash , Fidler, Jeff L. , Griesemer, Adam , Fowler, Kathryn J. , Heimbach, Julie K. , Fidler, Jeff L.

Mayo Clinic

American Journal of Roentgenology | April 11, 2019 | Volume: 213 | Issue: 1 | Pages: 65-76

10.2214/ajr.18.21064 | PMID 30973784 Get It

Epidemiology, Tumor Characteristics, and Survival in Patients With Primary Pancreatic Lymphoma
Mukhija, Dhruvika , Sohal, Davendra , Nagpal, Sajan Jiv Singh

Mayo Clinic

American Journal of Clinical Oncology | April 11, 2019 | Volume: 42 | Issue: 5 | Pages: 454-458

10.1097/coc.0000000000000544 | PMID 30950860 Get It

Introduction: Primary pancreatic lymphoma (PPL) is an extranodal manifestation of non-Hodgkin lymphoma originating in the pancreas, which constitutes <1% of all pancreatic neoplasms. Because of the rarity of the disease, most data on PPL are derived from case reports and small case series. To provide better insight into the epidemiology, treatment, and outcomes of these patients, we conducted an analysis of patients with PPL from the Surveillance, Epidemiology and End Results (SEER) database, which is presented in this study. Methods: Patients with PPL were identified using the International Classification of Disease for Oncology, third edition histology codes for lymphoma (9590/3-9734/3), with pancreas (C25.0-C25.9) listed as the primary disease site. We collected data on patient demographics, year of diagnosis, primary tumor site, histology, first line of treatment received, and survival until death or last follow-up for the period 1973-2014. Results: Overall, 835 patients were included. The median (range) age of the study population was 67 (2 to 98) years. The median (95% confidence interval) overall survival for the cohort was 53 (37 to 73) months. On univariable analyses, age, stage, and use of chemotherapy were statistically associated with improved overall survival. Besides these factors, white race was associated with improved cause-specific survival on multivariable analysis. Conclusions: This large population-based series describes PPL in detail. Younger age, white race, early stage, and initial treatment with chemotherapy are associated with improved survival in patients with PPL.
Mandibular Spatial Reorientation and Morphological Alteration of Crouzon and Apert Syndrome
Lu, Xiaona , Sawh‐Martinez, Rajendra , Forte, Antonio J. , Wu, Robin T. , Cabrejo, Raysa, Wilson, Alexander T. , Steinbacher, Derek M., Alperovich, Michael , Alonso, Nivaldo , Persing, John A. , Forte, Antonio Jorge

Mayo Clinic

Annals of Plastic Surgery | April 11, 2019 | Volume: 83 | Issue: 5 | Pages: 568-582

10.1097/sap.0000000000001811 | PMID 31008788 Get It

Background From infancy to adulthood, the mandible develops increased ramus height, prominence of the chin, and laterally widened gonial angles. In Crouzon and Apert syndromes, both relative retrognathia and prognathic jaws have been reported. Growth is influenced by a variety of factors, including the growth and relative position of the skull base, functional coordination, and the spatial influence of the laryngopharynx. Thus, this study aimed to explore in detail the evolution of the mandible in both syndromes and its relationship with the entire facial structure and skull base. Methods One hundred twenty-three preoperative computed tomographic scans (Crouzon, n = 36; Apert, n = 33; control, n = 54) were included and divided into 5 age subgroups. Computed tomographic scans were measured using Materialise software. Cephalometrics relating to the mandible, facial structures, and cranial base were collected. Statistical analyses were performed using t test and statistical power analysis. Results In Crouzon syndrome, the angle between the cranial base and gnathion was increased prior to 6 months of age by 10.29 degrees (P < 0.001) and by adulthood to 11.95 degrees (P = 0.003) compared with normal. After 6 months of age, the distance between bilateral mandibular condylions (COR-COL) was narrower by 15% (P < 0.001) in Crouzon syndrome compared with control subjects. Before 6 months of age, Apert COR-COL decreased 16% (P < 0.001) compared with control subjects and 13% (P = 0.006) narrower than Crouzon. During 2 to 6 years of age, Apert mandibular ramus height caught up to, and became longer than, Crouzon by 12% (P = 0.011). The nasion-sella-articulare angle of the Apert skull was 5.04 degrees (P < 0.001) less than Crouzon overall. Conclusions In Crouzon syndrome, the changes of the spatial relationship of the mandible to the cranial base develop earlier than the mandibular shape deformity, whereas in Apert syndrome, the spatial and morphological changes are synchronous. The morphological changes of the mandible are disproportional in 3 directions, initially significant shortening of the mandibular width and length, and, subsequently, reduced height. Crouzon has more shortening in mandibular height compared with Apert, reflecting the more shortened posterior cranial base length. The narrowed angle between the mandible and the posterior cranial base in Apert skulls is consistent with the more limited nasopharyngeal and oropharyngeal airway space.
Nonhuman leukocyte antigen antibodies that have impact in the heart transplant patient
Reddy, Yogesh N.V. , Pereira, Naveen L. , Nishimura, Rick

Mayo Clinic

Current Opinion in Organ Transplantation | April 11, 2019 | Volume: 24 | Issue: 3 | Pages: 279-285

10.1097/mot.0000000000000642 | PMID 31090636 Get It

Purpose of review Despite human leukocyte antigen (HLA) matching and monitoring for donor-specific HLA antibodies, antibody-mediated rejection and chronic rejection in the form of allograft vasculopathy and chronic graft dysfunction continue to occur. There has been increasing interest in non-HLA antibodies as mediators of these changes. Recent findings In this review, we discuss the recent literature describing the importance of non-HLA antibodies in organ transplantation and summarize the literature evaluating such antibodies in heart transplantation. Summary Monitoring of non-HLA antibodies requires additional measurement standardization and correlation of specific antibodies with outcomes. However, there is promise that identification with newer immunoproteomic techniques and therapy toward such antibodies may improve long-term graft outcomes and decrease acute rejection and allograft vasculopathy.
Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum
Mahr, Alfred , Jayne, David , Mahr, Alfred , Jayne, David , Specks, Ulrich

Mayo Clinic

Rheumatology | April 11, 2019 | Volume: 58 | Issue: 10 | Pages: 1707-1709

10.1093/rheumatology/kez148 | PMID 31049594 Get It

Y-V Alar Base Reduction
Hamilton, Grant

Mayo Clinic

Ear, Nose & Throat Journal | April 11, 2019 | Volume: 93 | Issue: 3 | Pages: 98-102

10.1177/014556131409300305 Get It

Improvement in Oxygenation Utilizing Transpulmonary Pressure Monitoring for Optimal Positive End-Expiratory Pressure in Pediatric Acute Respiratory Distress Syndrome: A Case Report
Gleich, Stephen J. , Schiltz, Brenda , Ouellette, Yves , Aganga, Devon O. , Schiltz, Brenda M, Baker, James E.

Mayo Clinic

A&A Practice | April 11, 2019 | Volume: 13 | Issue: 3 | Pages: 114-117

10.1213/xaa.0000000000001008 | PMID 30985319 Get It

In severe pediatric acute respiratory distress syndrome, data are lacking on methods to measure and set optimal positive end-expiratory pressure. We present a 2-year-old girl with Trisomy 21 who developed severe pediatric acute respiratory distress syndrome and refractory hypoxemia from human metapneumovirus pneumonia. Esophageal manometry was utilized to measure transpulmonary pressure, and positive end-expiratory pressure was increased to 19 cm H 2 O, resulting in rapid improvement in oxygenation. Hemodynamics remained adequate without intervention. The patient improved and survived without sequelae. Our case suggests that transpulmonary pressure monitoring should be studied as an adjunct to improve outcomes in pediatric acute respiratory distress syndrome.
Targeted Sequencing Study to Uncover Shared Genetic Susceptibility Between Peripheral Artery Disease and Coronary Heart Disease—Brief Report
Safarova, Maya , Fan, Xiao , Austin, Erin , Zuydam, Natalie Van, Hopewell, Jemma C. , Schaid, Daniel J. , Safarova, Maya S, Austin, Erin E, Hopewell, Jemma C , Kullo, Iftikhar J.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | April 11, 2019 | Volume: 39 | Issue: 6 | Pages: 1227-1233

10.1161/atvbaha.118.312128 | PMID 31070467 Get It

Objective— It is unclear to what extent genetic susceptibility variants are shared between peripheral artery disease (PAD) and coronary heart disease (CHD), both manifestations of atherosclerotic vascular disease. We investigated whether common and low-frequency/rare variants in loci associated with CHD are also associated with PAD. Approach and Results— Targeted sequencing of 41 genomic regions associated with CHD in genome-wide association studies was performed in 1749 PAD cases (65±11 years, 61% men) and 1855 controls (60±11 years, 56% men) of European ancestry. PAD cases had a resting/postexercise ankle-brachial index ≤0.9, or history of lower extremity revascularization; controls had no history of PAD. We tested the association of common (defined as minor allele frequency ≥5%) variants with PAD assuming an additive genetic model with adjustment for age and sex. To identify low-frequency/rare variants (minor allele frequency <5%) associated with PAD, we conducted gene-level analyses using sequence kernel association test and permutation test. After Bonferroni correction, we found common variants in SH2B3, ABO , and ZEB2 to be associated with PAD ( P <4.5×10 −5 ). At the gene level, the strongest associations were for LPL and SH2B3 . Conclusions— Targeted sequencing of 41 genomic regions associated with CHD revealed several common variants/genes to be associated with PAD, highlighting the basis of shared genetic susceptibility between CHD and PAD.
Clopidogrel Pharmacogenetics
Pereira, Naveen L. , Rihal, Charanjit S. , So, Derek , Rosenberg, Yves , Lennon, Ryan J. , Mathew, Verghese, Weinshilboum, Richard M., Wang, Liewei , Baudhuin, Linnea M. , Hasan, Ahmed , Iturriaga, Erin , Fu, Yi-Ping, Geller, Nancy L. , Bailey, Kent R. , Farkouh, Michael E. , Rihal, Charanjit S. , Lennon, Ryan J. , Goodman, Shaun G. , Lerman, Amir

Mayo Clinic

Circulation: Cardiovascular Interventions | April 11, 2019 | Volume: 12 | Issue: 4 | Pages: No page available

10.1161/circinterventions.119.007811 | PMID 30998396 Get It

Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel active metabolite levels and high on-treatment platelet reactivity resulting in increased risk of major adverse cardiovascular events, especially after percutaneous coronary intervention. The Food and Drug Administration has issued a black box warning advising practitioners to consider alternative treatment in CYP2C19 poor metabolizers who might receive clopidogrel and to identify such patients by genotyping. However, routine clinical use of genotyping for CYP2C19 loss-of-function alleles in patients undergoing percutaneous coronary intervention is not recommended by clinical guidelines because of lack of prospective evidence. To address this critical gap, TAILOR-PCI (Tailored Antiplatelet Initiation to Lessen Outcomes due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention) is a large, pragmatic, randomized trial comparing point-of-care genotype-guided antiplatelet therapy with routine care to determine whether identifying CYP2C19 loss-of-function allele patients prospectively and prescribing alternative antiplatelet therapy is beneficial.
Lipohyperplasia of the Parathyroid Glands
Landry, April M., Hinni, Michael, Carter, John M.

Mayo Clinic

Ear, Nose & Throat Journal | April 11, 2019 | Volume: 91 | Issue: 10 | Pages: 441-443

10.1177/014556131209101009 Get It

Parathyroid lipohyperplasia is an extremely rare cause of hyperparathyroidism. According to a MEDLINE search, there have been only 9 previously reported cases of parathyroid lipohyperplasia in the English-language literature. We report a new case of parathyroid lipohyperplasia, with a brief discussion of this rare disease process.